Renal Outcome with Empagliflozin in non-diabetic Chronic Kidney Disease Patients: A Randomized Control Trial - Trial ANZCTR12622000265774
Access comprehensive clinical trial information for ANZCTR12622000265774 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Zara Nisar and is currently Not yet recruiting. The study focuses on Chronic kidney disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Australian New Zealand Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zara Nisar
Timeline & Enrollment
Phase 2/3
Feb 21, 2022
Mar 21, 2022
Primary Outcome
Change in the baseline of eGFR. This will be measured according to the EPI-CKD equation. It will be done by a blood test.
Summary
Chronic kidney disease is a serious public health problem as it is one of the major causes of hospitalization worldwide. Despite receiving medical treatment, the outcomes remain either fast progression to dialysis or transplantation. The findings of the EMPEROR Reduced trial and DAPA CKD trials support our rationale to further explore the effects of the drug beyond the diabetic patients. we would further like to explore the effects on just CKD patients and how does this drug affect the progression of CKD. It is hypothesized that by including this drug with the standard of treatment, it will slow down the progression of Chronic kidney disease to next stage.
ICD-10 Classifications
Data Source
Australian New Zealand Clinical Trials Registry
ANZCTR12622000265774
Non-Device Trial